Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas and Welldoc Enter into Strategic Alliance for Digital Therapeutics

11/20/2019 | 08:00pm EDT

Astellas Pharma Inc. and Welldoc, Inc. announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar®(1) in Japan and certain other Asian markets for patients with diabetes, collaborate to broaden the adoption of BlueStar® in the U.S. market, and jointly develop and commercialize digital therapeutics in other therapeutic areas globally. BlueStar® is a digital health solution that is cleared by the U.S. Food and Drug Administration (FDA)- in the United States for use by healthcare providers and their patients aged 18 years and older who have type 1 or type 2 diabetes. BlueStar® not only assists patients in managing their disease by capturing, storing, and transmitting blood glucose data and tracking medication, diet, activity and exercise, but also uses individual patient treatment data and machine learning to provide tailored motivational, behavioral, and educational coaching messages to aid in diabetes self-management. FDA initially cleared BlueStar® in 2010 and since then Welldoc has received 6 additional 510(k) clearances from the FDA. In the United States, BlueStar® is marketed as both a prescription and non-prescription digital health solutions for diabetes. BlueStar® is currently marketed in the U.S. and Canada. Under the terms of the agreement, Astellas will make an upfront payment of $15 million to Welldoc. In addition, the agreement includes development and commercialization milestones as well as royalties on any future product sales. The impact of this alliance on Astellas' financial results in the fiscal year ending March 31, 2020 is expected to be limited. BlueStar®: BlueStar® is a digital health solution that is cleared by FDA for use by adults with type 1 or type 2 diabetes. In addition to assisting patients in managing their disease in line with the guidelines compiled by the American Association of Diabetes Educators (AADE), namely, taking medication, eating well, and being active, it offers a management method for individual patients' blood glucose levels made possible by machine learning and artificial intelligence that uses compiled treatment data to provide tailored coaching messages to aid in diabetes self-management. BlueStar® also comes with a diagnosis support system for physicians, which allows patients to share data on blood glucose levels, medication, and physical conditions, as well as the status of progress, with physicians before examination. Astellas' Rx+™ Business: A business that leverages the expertise and knowledge of Astellas, which have been cultivated through its prescription drug (Rx) business, integrates innovative medical technology with cutting-edge technology in different fields, contributes to patients through Patient Journey (overall medical care, including diagnostic, preventive, therapeutic, and prognostic care), and creates new revenue streams separate from Astellas' core Rx products.


© S&P Capital IQ 2019
All news about ASTELLAS PHARMA INC.
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Prog..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approac..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in E..
MT
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
PU
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVREN..
AQ
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) fo..
PU
More news
Financials
Sales 2022 1 325 B 12 044 M 12 044 M
Net income 2022 196 B 1 779 M 1 779 M
Net cash 2022 478 B 4 341 M 4 341 M
P/E ratio 2022 17,7x
Yield 2022 2,65%
Capitalization 3 500 B 31 855 M 31 819 M
EV / Sales 2022 2,28x
EV / Sales 2023 1,92x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 889,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura Representative Director, VP & Head-Finance
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.18.51%31 855
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456